Despite Denial, Bass Launches New Attack On Acorda Patents
Undaunted by recent decisions rejecting its petitions for America Invents Act reviews of two patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra, an organization run by hedge fund manager Kyle...To view the full article, register now.
Already a subscriber? Click here to view full article